T1	Participants 48 75	cytomegalovirus retinopathy
T2	Participants 630 638	Patients
T3	Participants 1545 1589	Patients receiving higher doses of foscarnet
T4	Participants 1831 1873	patients with cytomegalovirus retinopathy.
